Home / Business and Economy / Adaptive Biotech Splits to Boost Core Business
Adaptive Biotech Splits to Boost Core Business
28 Jun
Summary
- Company announced a $300 million convertible notes offering.
- Adaptive Biotechnologies is separating its MRD and immune medicine businesses.
- BTIG maintained a Buy rating on ADPT with a $22 price target.
Adaptive Biotechnologies Corporation is undertaking a significant strategic maneuver by separating its immune medicine business from its core focus on MRD (minimal residual disease) applications. This decision follows an upsized convertible notes offering, which raised $300 million, surpassing the initial $250 million target.
BTIG recently reaffirmed its Buy rating on Adaptive Biotechnologies (NASDAQ:ADPT), setting a $22 price target. The firm views the separation of the immune medicine unit favorably, considering it non-core and a potential catalyst for unlocking value within the MRD business. Despite some minor share fluctuations related to the convertible notes, BTIG expressed confidence after discussions with management, noting strong momentum across all MRD applications.
The company's operations involve developing an immune medicine platform, offering services and products like immunoSEQ, clonoSEQ, cellular therapy, and vaccines.
